- Home
- OPTN vs SCLX Comparison
OPTN vs SCLX Comparison
Compare OPTN & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- SCLX
- Stock Information
- Founded
- OPTN 2010
- SCLX 2011
- Country
- OPTN United States
- SCLX United States
- Employees
- OPTN N/A
- SCLX N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- OPTN Health Care
- SCLX Health Care
- Exchange
- OPTN Nasdaq
- SCLX Nasdaq
- Market Cap
- OPTN 92.8M
- SCLX 51.3M
- IPO Year
- OPTN 2017
- SCLX N/A
- Fundamental
- Price
- OPTN $9.39
- SCLX $4.39
- Analyst Decision
- OPTN Hold
- SCLX Strong Buy
- Analyst Count
- OPTN 3
- SCLX 4
- Target Price
- OPTN $9.00
- SCLX $396.67
- AVG Volume (30 Days)
- OPTN 41.7K
- SCLX 198.6K
- Earning Date
- OPTN 05-20-2025
- SCLX 05-16-2025
- Dividend Yield
- OPTN N/A
- SCLX N/A
- EPS Growth
- OPTN N/A
- SCLX N/A
- EPS
- OPTN N/A
- SCLX N/A
- Revenue
- OPTN $78,226,000.00
- SCLX $56,590,000.00
- Revenue This Year
- OPTN $30.49
- SCLX $115.30
- Revenue Next Year
- OPTN $13.51
- SCLX $73.33
- P/E Ratio
- OPTN N/A
- SCLX N/A
- Revenue Growth
- OPTN 10.20
- SCLX 21.07
- 52 Week Low
- OPTN $4.82
- SCLX $3.60
- 52 Week High
- OPTN $20.03
- SCLX $80.50
- Technical
- Relative Strength Index (RSI)
- OPTN 76.15
- SCLX 33.15
- Support Level
- OPTN $9.14
- SCLX $4.51
- Resistance Level
- OPTN $9.45
- SCLX $6.13
- Average True Range (ATR)
- OPTN 0.08
- SCLX 0.87
- MACD
- OPTN -0.07
- SCLX 0.14
- Stochastic Oscillator
- OPTN 80.71
- SCLX 31.21
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.